Alaska Section of Epidemiology (SOE) Guidance for Coronavirus Disease 2019 (COVID-19) Testing in Alaska

August 11, 2022

Key Points

- All facilities or organizations that administer or interpret COVID-19 testing must laboratory-confirmed
 cases of COVID-19 to SOE preferentially via an electronic method. As of August 8, 2022, facilities that
 are not able to report NEGATIVE results electronically should discontinue sending them via fax.
 Detailed Alaska Reporting Guidance can be found here.
- SOE staff can be reached for consultation at 907-269-8000 or 800-478-0084 (after-hours).
- The Alaska State Public Health Laboratories in Anchorage (ASPHL) and Fairbanks (ASVL) are running specimens 5 days per week (M–F, excluding holidays) at both facilities. Specimens must be submitted with a Respiratory Pathogen Test Request form.
- Testing locations can be found here. Sites performing public testing should provide updates on their testing hours and information.
- The testing landscape of COVID-19 has evolved over the past 3 years with more readily available athome testing and reduction of free community testing sites. Therefore, overarching principles for COVID-19 response include 1) symptomatic people should act to minimize transmission to others by isolating until after symptoms have improved; 2) testing can assist in confirming a diagnosis and ensuring that those with high-risk conditions can be connected to treatment services; and 3) pharmaceutical interventions (e.g., vaccination and treatment) and non-pharmaceutical interventions (e.g., masks, social distancing, and improving ventilation) can reduce transmission and/or reduce severe outcomes from COVID-19.

Test Anybody in Alaska Who Is Experiencing Symptoms of COVID-19

- Symptomatic people should be tested regardless of their vaccination status. If testing is not feasible, people should isolate until they are at least fever free for >24 hours and have improvement of symptoms to avoid spreading any respiratory infections to others.
 - o Symptoms of COVID-19 may include any of the following: fever, cough, shortness of breath, difficulty breathing, chills, decreased appetite, diminished sense of taste or smell, diarrhea, fatigue, headache, muscle/joint aches, nausea, rash, rigors, runny nose, sore throat, or sputum production.
- Antigen testing is an acceptable first-line test for COVID-19 infection in most scenarios. Molecular tests are not as widely available as in the past.
 - Consider serial antigen testing or confirmatory testing with a NAAT for a negative antigen test result especially if the person is at high risk of severe disease and may be eligible for treatments.
- Given the wide availability of self-testing resources, organizations with difficulty funding and maintaining operations for on-site COVID testing programs could consider accepting antigen self-test results.

Screening Testing for Asymptomatic Persons

Requirements or recommendations for routine screening may be present in some venues or local communities following an exposure or due to local/employer/business policy.

- Upon admission to a health care facility based on facility policy.
 - o Residents and staff living or working in nursing homes and long-term care facilities (LTCF) should follow CDC guidance.
 - o Questions specific to these settings can be directed to the LTCF facility team at hss.dph.epi.ltc.covidreporting@alaska.gov
- CDC guidance for testing of healthcare workers is available here.
- Information for those who work or live at a seafood processing facility is available here.
- Additional information on considerations for screening testing in various settings including schools

- and non-healthcare workplaces is available on the CDC COVID-19 website.
- Organizations and entities not covered by specific CDC guidance should make decisions about screening
 policies based on their own risk assessments of the populations they serve or employ.
- CDC's travel requirements can be found here.

Isolation and Precautions Guidance (updated August 11, 2022)

- CDC's isolation guidance for the general public is available here.
- Quarantine is <u>no longer recommended for the general public</u>; however, persons who are exposed should consider taking certain precautions to include watching for symptoms and testing.
- Guidance specific to health care workers is available <u>here</u>.
- Guidance specific to non-hospital health care settings is available here.
- Guidance specific to K-12 school settings is available here.
- Guidance specific to certain high-risk congregate settings is available at other sites (e.g., <u>correctional facilities</u>, <u>homeless shelters</u>.)
- Asymptomatic persons who had tested positive on a molecular test may discontinue isolation if they have two subsequent negative molecular tests obtained at least 24 hours apart. If at any point clinically compatible symptoms develop, the patient should be placed into isolation and retested.

At-Home or OTC Testing

The Alaska over-the-counter (OTC) COVID-19 testing guidance is available here.

- Positive OTC tests that are self-collected and self-interpreted do not have to be reported to SOE.
- CDC information about at-home testing is available here.

Specimen Type and Priority (based on CDC Guidance)

- FDA guidance on swabs and specimen transport media is available <u>here</u>.
- An NP collection guidance video is available <u>here</u>. A self-collection guidance video is available <u>here</u>.
- Maintain proper infection control when collecting specimens.

Sequencing and Variant Detection

- All positive specimens collected in UTM/VTM or any Hologic Aptima Direct Load tubes should be submitted to ASVL for sequencing. Re-collection is not necessary; submit the remainder of the specimen.
- Specimens that are *not* collected in UTM/VTM or Hologic Aptima Direct Load tubes cannot be sequenced (this includes most specimens tested on rapid antigen assays).
- Specimens sent within 2 weeks of collection are prioritized.
- Send positive specimens as Category B samples to ASVL in Fairbanks, per <u>shipping instructions</u>.
 - o For more information about sequencing SARS-CoV-2 in Alaska, click here.
 - o For the most recent Alaska SARS-CoV-2 genomics results, please visit the genomics dashboard.

Serologic Testing

- SARS-CoV-2 serologic test results are not reportable; Alaska Reporting Guidance can be found here.
- CDC's interim guidelines on antibody testing are here.
- Regardless of their serology results, symptomatic patients should be tested for COVID-19 via molecular or antigen methods.
- <u>CDC does not recommend</u> antibody testing after vaccination. One reason why antibody testing is
 not recommended following vaccination is that cell-mediated immunity may contribute to vaccineinduced immunity, and cell-mediated immunity is not assessed by antibody assays.
- <u>IDSA recommends</u> that antibody tests not be used to make decisions about whether personal protective equipment is needed.